A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2015
Price : $35 *
At a glance
- Drugs Vintafolide (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 14 Jul 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 11 Mar 2014 Planned End Date changed from 1 Jun 2015 to 1 Mar 2015 as reported by ClinicalTrial.gov record.
- 11 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrial.gov record.